loading
Precedente Chiudi:
$1.79
Aprire:
$1.82
Volume 24 ore:
415.40K
Relative Volume:
0.64
Capitalizzazione di mercato:
$48.63M
Reddito:
-
Utile/perdita netta:
$-21.24M
Rapporto P/E:
-2.1721
EPS:
-0.8379
Flusso di cassa netto:
$-22.47M
1 W Prestazione:
+26.83%
1M Prestazione:
-22.88%
6M Prestazione:
-63.82%
1 anno Prestazione:
-85.84%
Intervallo 1D:
Value
$1.75
$1.92
Intervallo di 1 settimana:
Value
$1.36
$1.92
Portata 52W:
Value
$1.14
$13.51

Skye Bioscience Inc Stock (SKYE) Company Profile

Name
Nome
Skye Bioscience Inc
Name
Telefono
(858) 410-0266
Name
Indirizzo
11250 EL CAMINO REAL, SUITE 100, SAN DIEGO
Name
Dipendente
16
Name
Cinguettio
Name
Prossima data di guadagno
2024-11-07
Name
Ultimi documenti SEC
Name
SKYE's Discussions on Twitter

Confronta SKYE con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
 icon
SKYE
Skye Bioscience Inc.
3.10 12.89M 0 0 0 0.00
 icon
MOBBW
Mobilicom Limited Warrants
0.255 398.00M 0 0 0 0.00
 icon
GOODO
Gladstone Commercial Corporation
19.99 372.90M 0 0 0 0.00
 icon
PSNYW
Polestar Automotive Holding Uk
0.1685 343.35M 2.07B -1.42B -1.37B -0.6765
 icon
JUNE
Dhandho Junoon Etf
10.76 215.97M 0 0 0 0.00
 icon
SHMD
Schmid Group N V
3.64 126.17M 0 0 0 0.00

Skye Bioscience Inc Stock (SKYE) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-02-28 Iniziato William Blair Outperform
2024-09-30 Iniziato Scotiabank Sector Outperform
2024-09-10 Iniziato JMP Securities Mkt Outperform
2024-07-09 Iniziato Craig Hallum Buy
2024-05-23 Iniziato Cantor Fitzgerald Overweight
2024-04-12 Iniziato Oppenheimer Outperform
Mostra tutto

Skye Bioscience Inc Borsa (SKYE) Ultime notizie

pulisher
08:06 AM

Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

08:06 AM
pulisher
Apr 23, 2025

Skye Bioscience stock target holds at $15 on obesity drug outlook - Investing.com

Apr 23, 2025
pulisher
Apr 22, 2025

William Blair Forecasts Skye Bioscience Q2 Earnings - MarketBeat

Apr 22, 2025
pulisher
Apr 22, 2025

(04/22/25) SKYE: A Speculative Play in the Weight Loss Drug Space - moneyshow.com

Apr 22, 2025
pulisher
Apr 21, 2025

SKYE’s Market Ups and Downs: What’s Behind the 2023 Stock Performance? - investchronicle.com

Apr 21, 2025
pulisher
Apr 19, 2025

Skye Bioscience, Inc. (NASDAQ:SKYE) Given Average Rating of “Buy” by Analysts - Defense World

Apr 19, 2025
pulisher
Apr 19, 2025

William Blair Predicts Skye Bioscience Q1 Earnings - Defense World

Apr 19, 2025
pulisher
Apr 19, 2025

Brokers Offer Predictions for Skye Bioscience Q1 Earnings - Defense World

Apr 19, 2025
pulisher
Apr 19, 2025

Analysts Set Skye Bioscience, Inc. (NASDAQ:SKYE) PT at $16.60 - Defense World

Apr 19, 2025
pulisher
Apr 18, 2025

Brokers Issue Forecasts for Skye Bioscience Q2 Earnings - Defense World

Apr 18, 2025
pulisher
Apr 16, 2025

A Weight Loss Drug Candidate Essentially For Free As Skye Bioscience Is Trading At Cash Value - Seeking Alpha

Apr 16, 2025
pulisher
Apr 15, 2025

Mural's Big Shake-Up, Skye's Weight Loss Win, And Janover's Crypto Bet - Finimize

Apr 15, 2025
pulisher
Apr 15, 2025

Skye Bioscience reports promising obesity treatment study By Investing.com - Investing.com South Africa

Apr 15, 2025
pulisher
Apr 15, 2025

Skye Bioscience's Obesity Candidate Shows 30% Weight Loss When Combined With Eli Lilly's Blockbuster Drug In Animal Models - Benzinga

Apr 15, 2025
pulisher
Apr 15, 2025

Skye Bioscience (SKYE) Schedules Key Meetings at Biopharma Symposium - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

Crude Oil Moves Lower; Citigroup Posts Upbeat Results - Benzinga

Apr 15, 2025
pulisher
Apr 15, 2025

Skye Bioscience soars after experimental weight-loss drug shows promise in mice - TradingView

Apr 15, 2025
pulisher
Apr 15, 2025

Nasdaq Surges 100 Points; Bank of America Earnings Top Views - Benzinga

Apr 15, 2025
pulisher
Apr 15, 2025

Skye Bioscience Demonstrates Over 30% Weight Loss With Nimacimab And Tirzepatide Combination In Preclinical Model - marketscreener.com

Apr 15, 2025
pulisher
Apr 15, 2025

Skye Bioscience's (SKYE) Nimacimab Shows Promising Weight Loss R - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

Skye Bioscience Demonstrates Over 30% Weight Loss with Nimacimab - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

Skye Bioscience Demonstrates Over 30% Weight Loss with Nimacimab and Tirzepatide Combination in Preclinical Model | SKYE Stock News - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

Skye Bioscience reports promising obesity treatment study - Investing.com

Apr 15, 2025
pulisher
Apr 15, 2025

Skye Bioscience Demonstrates Over 30% Weight Loss with - GlobeNewswire

Apr 15, 2025
pulisher
Apr 15, 2025

Skye Bioscience (SKYE) Demonstrates Over 30% Weight Loss with Nimacimab and Tirzepatide Combination in Preclinical Model - StreetInsider

Apr 15, 2025
pulisher
Apr 15, 2025

Revolutionary Obesity Drug Combo Shows 30% Weight Loss Success in Latest Trial Data - Stock Titan

Apr 15, 2025
pulisher
Apr 15, 2025

Skye Bioscience to Conduct Meetings at Piper Sandler Conference - GuruFocus

Apr 15, 2025
pulisher
Apr 14, 2025

Major Obesity Drug Developer Skye Bio Takes Center Stage at Prestigious Investor Conference - Stock Titan

Apr 14, 2025
pulisher
Apr 11, 2025

Skye Bioscience (NASDAQ:SKYE) Shares Down 50.8% – Here’s Why - Defense World

Apr 11, 2025
pulisher
Apr 11, 2025

Skye Bioscience (NASDAQ:SKYE) Trading Down 50.8% – What’s Next? - Defense World

Apr 11, 2025
pulisher
Apr 08, 2025

Skye Bioscience, Inc. Investigated by Shareholder Rights AdvocatesInvestors Should Contact Levi & Korsinsky Regarding Potential Securities Law ViolationsSKYE - ACCESS Newswire

Apr 08, 2025
pulisher
Apr 02, 2025

Charles Schwab Investment Management Inc. Has $176,000 Position in Skye Bioscience, Inc. (NASDAQ:SKYE) - Defense World

Apr 02, 2025
pulisher
Apr 02, 2025

Charles Schwab Investment Management Inc. Grows Stock Position in Skye Bioscience, Inc. (NASDAQ:SKYE) - Defense World

Apr 02, 2025
pulisher
Apr 02, 2025

10,142 Shares in Skye Bioscience, Inc. (NASDAQ:SKYE) Acquired by Virtu Financial LLC - Defense World

Apr 02, 2025
pulisher
Apr 02, 2025

Virtu Financial LLC Invests $29,000 in Skye Bioscience, Inc. (NASDAQ:SKYE) - Defense World

Apr 02, 2025
pulisher
Mar 30, 2025

Skye Bioscience, Inc. (NASDAQ:SKYE) Receives Consensus Rating of “Buy” from Analysts - Defense World

Mar 30, 2025
pulisher
Mar 30, 2025

Skye Bioscience, Inc. (NASDAQ:SKYE) Receives $18.00 Average Price Target from Analysts - Defense World

Mar 30, 2025
pulisher
Mar 28, 2025

Skye Bioscience, Inc. (NASDAQ:SKYE) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat

Mar 28, 2025
pulisher
Mar 25, 2025

Skye Bioscience, Inc. (PNK:SKYE) Q4 2024 Earnings Call Transcript - MSN

Mar 25, 2025
pulisher
Mar 25, 2025

Skye Bioscience (NASDAQ:SKYE) Receives Outperform Rating from William Blair - MarketBeat

Mar 25, 2025
pulisher
Mar 25, 2025

Skye Bioscience promotes Tu Diep to COO post - The Pharma Letter

Mar 25, 2025
pulisher
Mar 25, 2025

Skye Bioscience (NASDAQ:SKYE) Price Target Cut to $14.00 by Analysts at Craig Hallum - MarketBeat

Mar 25, 2025
pulisher
Mar 24, 2025

Skye Bioscience (NASDAQ:SKYE) Announces Quarterly Earnings Results - MarketBeat

Mar 24, 2025
pulisher
Mar 23, 2025

Skye Bioscience’s SWOT analysis: novel obesity drug stock faces pivotal year - Investing.com Canada

Mar 23, 2025
pulisher
Mar 23, 2025

Craig Hallum Cuts Skye Bioscience (NASDAQ:SKYE) Price Target to $14.00 - Defense World

Mar 23, 2025
pulisher
Mar 23, 2025

Skye Bioscience’s (SKYE) “Outperform” Rating Reiterated at William Blair - Defense World

Mar 23, 2025
pulisher
Mar 23, 2025

Craig Hallum Issues Pessimistic Forecast for Skye Bioscience (NASDAQ:SKYE) Stock Price - Defense World

Mar 23, 2025

Skye Bioscience Inc Azioni (SKYE) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$20.59
price up icon 0.24%
$69.69
price up icon 1.06%
$32.20
price up icon 0.53%
$23.46
price down icon 36.06%
$102.02
price down icon 15.36%
biotechnology ONC
$244.90
price down icon 4.40%
Capitalizzazione:     |  Volume (24 ore):